Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Perspective

Is Lycopene an Effective Agent for Preventing Prostate Cancer?

Michael B. Sporn and Karen T. Liby
Michael B. Sporn
Department of Pharmacology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen T. Liby
Department of Pharmacology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.CAPR-13-0026 Published May 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The role of lycopene, an open-chain carotenoid found in tomatoes and devoid of retinoid activity, as an anticarcinogenic, chemopreventive agent, especially for use in prostate cancer, is still under active investigation. In this issue, Qui and colleagues show that lycopene induces responses in human prostate epithelial cells that are antiproliferative, antioxidative, and anti-inflammatory, as well as downregulating targets in the androgen receptor signaling pathway. In this perspective, we review aspects of the molecular and cellular biology of lycopene that support its use for prevention of prostate cancer. Whether lycopene itself or its metabolites induce most of its benefits is still uncertain. At present, meta-analysis of clinical studies of lycopene for prevention of prostate cancer in men does not yet support the definitive clinical use of this carotenoid in a preventive setting. Cancer Prev Res; 6(5); 384–6. ©2013 AACR.

See related article by Qiu et al., p. 419

Development of a safe and effective drug for clinical chemoprevention of prostate cancer remains an important goal. This is particularly significant for prostate cancer because of the long-standing controversy on the management of early lesions, namely the differences in opinion on surgery versus “watchful waiting.” If there were a generally accepted potent and safe chemopreventive drug with essentially no side effects, much of the controversy would disappear. Although antagonism of the androgen receptor has yielded effective drugs for clinical chemoprevention of prostate cancer, this too remains a controversial area, and the use of such drugs is not universally accepted.

Thus, in this context the emergence of lycopene as a potential candidate for clinical chemoprevention has recently become a hot topic in prevention studies (1–3). There is a little question that lycopene, the red carotenoid pigment found in tomatoes and other red vegetables and fruits, is an exceptionally safe molecule for use in humans. Millions of people have been ingesting lycopene for centuries with apparently no detectable side effects. Structurally like β-carotene, lycopene is a 40-carbon polyisoprenoid molecule; its red color is the result of its large number of conjugated double bonds (see Fig. 1), which also make it a uniquely potent agent for quenching of reactive oxygen species, such as singlet oxygen (4). However, unlike β-carotene, lycopene is an open chain molecule without terminal β-ionone rings and thus cannot serve as a precursor for all-trans-retinol, retinal, or retinoic acid—the active forms of “vitamin A.”

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Structures of lycopene, β-carotene, and all-trans-retinoic acid. β-carotene (40 carbon atoms) can serve as a dietary precursor of retinoids (20 carbon atoms) by the process of enzymatic cleavage, but lycopene (40 carbon atoms), which does not have a β-ionone ring, is not a retinoid precursor. Lycopene seems to be a much safer drug for chronic human administration than β-carotene.

The major questions that remain about lycopene and cancer are: (i) is it a potent enough agent for preventing human cancer, especially prostate cancer, and if so, (ii) what are the mechanisms and targets that are involved in its chemopreventive actions? As has happened in the development of many chemopreventive agents, the first indications of potential use have come from epidemiologic studies, which have suggested that consumption of large amounts of tomatoes and tomato products is associated with a lowered risk for developing prostate cancer (5, 6). Following these initial epidemiologic studies, there has been a flurry of activity to show that lycopene itself or its metabolites are the active agents in tomatoes for chemoprevention of prostate cancer in animals and to determine molecular mechanism of action and molecular targets.

In this context, the article by Qui and colleagues in this issue of Cancer Prevention and Research is a welcome contribution (7). The authors have shown that a range of proteins involved with anticarcinogenic and antioxidant responses, as well as cytoprotection, were upregulated in human prostate cells by lycopene treatment. These experiments were conducted at a physiologically relevant concentration of 2 μmol/L in tissue culture. In contrast, relevant procarcinogenic signal transduction pathways, such as androgen receptor signaling and the Akt/mTOR pathway, were downregulated. However, all these effects, although statistically significant, were less than 2-fold.

The results are notable in that they have been obtained by proteomic analysis, using new high-performance liquid chromatography-tandem mass spectrometry techniques, to identify specific proteins rather than by conventional gene array analysis; the latter method fails to measure protein expression. The results are also notable in that the authors have used highly relevant benign primary human prostate epithelial cells, which they have established in culture from surgical specimens, as the reader cells rather than less relevant malignant prostate cells such as LNCaP or PC-3. However, effects of lycopene on the various cells of the microenvironment, which can be so important for chemoprevention (8, 9) of cancer, were not evaluated in the present study. Overall, the present data suggest that lycopene is active in suppressing cancer initiation, promotion, and/or progression rather than at later stages of carcinogenesis; similar conclusions have previously been published.

There is no question that lycopene is indeed a multifunctional compound (1); in no way does it fit the current fashion for single-targeted drug therapy for either prevention or treatment of cancer. Not only is lycopene highly reactive toward oxygen and free radicals, it has a range of other mechanistic actions that are highly relevant to suppression of carcinogenesis. These include induction of apoptosis, antiproliferative, and antimetastatic activity, as well as the induction of cytoprotective “phase II” enzymes that inhibit the carcinogenic effects of many xenobiotics (1, 10). This latter effect is mediated by enhancement of the activity of the transcription factor, Nrf2, which results in increased transcription of cytoprotective genes regulated by the antioxidant response element on DNA. Lycopene was the most potent of a series of carotenoid molecules tested in this regard (10).

Moreover, it has been amply shown that lycopene itself is converted to a large number of metabolites. These conversions include isomerization of the trans-double bond system of the 40-carbon molecule, as well as cleavage and hydroxylation of many of the double bonds (11, 12). It has been suggested that, “there is limited experimental support for the (direct) antioxidant hypothesis as a major mechanism of lycopene's in vivo action” and that instead, “metabolic products of lycopene, the “lycopenoids”, may be more active than the parent molecule” (12). Furthermore, in this analysis, the desirable effects of the lycopenoids are suggested to be the result of alterations in gene expression.

The ultimate use of this entire approach to prostate cancer rests on its effectiveness in vivo, particularly in human subjects. Attempts to show preclinical efficacy in animal models of chemoprevention of prostate cancer have thus far not been impressive. Although statistically significant, while chemopreventive results have been reported in transgenic (TRAMP) and chemically induced (nitrosomethylurea plus testosterone) mouse (13) and rat (14) models, the effects were not particularly striking. Indeed, in the latter model, tomato powder was more effective than lycopene itself.

Final clinical proof of efficacy has been difficult to obtain. Oral administration of lycopene extracts to men with prostate cancer or benign prostatic hyperplasia caused major increases in lycopene levels in both prostate biopsies and plasma. However, in the same patients, no beneficial effects on biomarkers of oxidative stress and lipid peroxidation, such as 8-oxo-deoxyguanosine or malondialdehyde, were observed in either prostate tissue or plasma (15).

Similarly, 2 major recent retrospective studies (2, 3), which have surveyed many clinical trials for the potential benefits of lycopene supplements for prevention and treatment of prostate cancer, have failed to support any true optimism that lycopene itself will be an effective clinical chemoprevention drug. Fortunately, however, there is no evidence that lycopene can increase human cancer incidence, as has sadly happened with β-carotene in clinical trials (16–18). Although lycopene did decrease plasma PSA levels in some trials, the ultimate conclusion of the latest systematic review is that, “given the limited number of randomized clinical trials published, and the varying quality of existing studies, it is not possible to support, or refute, the use of lycopene for prevention or treatment of benign prostatic hypertrophy or prostate cancer” (3).

Perhaps, like many other natural products that can be shown to prevent cancer in experimental animals, lycopene is simply not potent enough to be a clinically useful drug. Concentrations in excess of 1 μmol/L are necessary to achieve biologically meaningful responses. Perhaps what is needed is to build upon what has already been shown, namely that lycopene does indeed have some chemopreventive activity but then to chemically modify this natural product scaffold to make more potent derivatives (19, 20). Such new semisynthetic derivatives hopefully will then be able to deliver the preventive results that are needed so urgently.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: M.B. Sporn

Writing, review, and/or revision of the manuscript: M.B. Sporn, K.T. Liby

Acknowledgments

The authors thank G. Tuson for her helpful assistance with the manuscript and figure.

  • Received January 25, 2013.
  • Accepted January 25, 2013.
  • ©2013 American Association for Cancer Research.

References

  1. 1.↵
    1. van Breemen RB,
    2. Pajkovic N
    . Multitargeted therapy of cancer by lycopene. Cancer Lett 2008;269:339–51.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Haseen F,
    2. Cantwell MM,
    3. O'Sullivan JM,
    4. Murray LJ
    . Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis 2009;12:325–32.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ilic D,
    2. Misso M
    . Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas 2012;72:269–76.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. DiMascio P,
    2. Kaiser S,
    3. Sies H
    . Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989;274:532–8.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Clinton SK
    . Lycopene: chemistry, biology, and implications for human health and disease. Nutr Rev 1998;56:35–51.
    OpenUrlPubMed
  6. 6.↵
    1. Giovannucci E
    . Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999;91:317–31.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Qui X,
    2. Yuan Y,
    3. Vaishnav A,
    4. Tessel MA,
    5. Nonn L,
    6. van Breemen RB
    . Effects of lycopene on protein expression in human primary prostatic epithelial cells. Cancer Prev Res 2013;6:419–27.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Albini A,
    2. Sporn MB
    . The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139–47.
    OpenUrlPubMed
  9. 9.↵
    1. Bissell MJ,
    2. Hines WC
    . Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011;17:320–9.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Ben-Dor A,
    2. Steiner M,
    3. Gheber L,
    4. Danilenko M,
    5. Dubi N,
    6. Linnewiel K,
    7. et al.
    Carotenoids activate the antioxidant response element transcription system. Mol Cancer Ther 2005;4:177–86.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Mein JR,
    2. Lian F,
    3. Wang XD
    . Biological activity of lycopene metabolites: implications for cancer prevention. Nutr Rev 2008;66:667–83.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Erdman JW Jr.,
    2. Ford NA,
    3. Lindshield BL
    . Are the health attributes of lycopene related to its antioxidant function? Arch Biochem Biophys 2009;483:229–35.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Konijeti R,
    2. Henning S,
    3. Moro A,
    4. Sheikh A,
    5. Elashoff D,
    6. Shapiro A,
    7. et al.
    Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate 2010;70:1547–54.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Boileau TW,
    2. Liao Z,
    3. Kim S,
    4. Lemeshow S,
    5. Erdman JW Jr.,
    6. Clinton SK
    . Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 2003;95:1578–86.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. van Breemen RB,
    2. Sharifi R,
    3. Viana M,
    4. Pajkovic N,
    5. Zhu D,
    6. Yuan L,
    7. et al.
    Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer Prev Res 2011;4:711–8.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Omenn GS,
    2. Goodman GE,
    3. Thornquist MD,
    4. Balmes J,
    5. Cullen MR,
    6. Glass A,
    7. et al.
    Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150–5.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Greenberg ER,
    2. Sporn MB
    . Antioxidant vitamins, cancer, and cardiovascular disease. N Engl J Med 1996;334:1189–90.
    OpenUrlCrossRefPubMed
  18. 18.↵
    The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–35.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Sporn MB,
    2. Liby KT,
    3. Yore MM,
    4. Suh N,
    5. Albini A,
    6. Honda T,
    7. et al.
    Platforms and networks in triterpenoid pharmacology. Drug Dev Res 2007;68:174–82.
    OpenUrlCrossRef
  20. 20.↵
    1. Liby KT,
    2. Sporn MB
    . Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 2012;64:972–1003.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Cancer Prevention Research: 6 (5)
May 2013
Volume 6, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Is Lycopene an Effective Agent for Preventing Prostate Cancer?
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Is Lycopene an Effective Agent for Preventing Prostate Cancer?
Michael B. Sporn and Karen T. Liby
Cancer Prev Res May 1 2013 (6) (5) 384-386; DOI: 10.1158/1940-6207.CAPR-13-0026

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Is Lycopene an Effective Agent for Preventing Prostate Cancer?
Michael B. Sporn and Karen T. Liby
Cancer Prev Res May 1 2013 (6) (5) 384-386; DOI: 10.1158/1940-6207.CAPR-13-0026
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The Case for a Pre-Cancer Genome Atlas (PCGA)
  • HPV-Positive Oropharyngeal Cancers
  • Indeterminate Pulmonary Nodules
Show more Perspective
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement